Deracoxib
Based on 1 publication(s) in Google Scholar
Deracoxib (SC 046; SC 59046), an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.96%
- CAS No.: 169590-41-4
- 화학식: C17H14F3N3O3S
- 분자량:397.37
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Deracoxib
More
Biological Activity
|
COX-2 |
Deracoxib (0-1000 μM, 72 h) inhibits the growth of osteosarcoma cell lines (POS, HMPOS and COS31) (IC50s ranged from 70 to 150 μM) and CMT-U27 cells (IC50 = 974.481 μM)[1][2].
Deracoxib (100-250 μM, 72 h) causes fragmentation of osteosarcoma cells and loss of their ability to adhere to the surface, while it only leads to a reduction in the number of fibroblasts, with the cells maintaining normal morphology[1].
Deracoxib (50-1000 μM, 72 h) induces G0/G1 phase arrest and cell apoptosis in CMT-U27 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:CMT-U27 cells
-
Concentration:250, 500, 1000 μM
-
Incubation Time:72 h
-
Result:Significantly increased the proportion of apoptotic cells.
-
Cell Line:CMT-U27 cells
-
Concentration:50, 100, 250, 500 and 1000 μM
-
Incubation Time:72 h
-
Result:Caused G0/G1 phase arrest at high concentrations (500-1000 μM).
Deracoxib (3 mg/kg, p.o., once daily until progressive disease progresses) is generally well tolerated by dogs and had antitumor activity against transitional cell carcinoma (TCC)[4].
Deracoxib (15 mg/kg, p.o., twcie daily for 26 days) prevents disease in murine Collagen (HY-NP010) induced arthritis[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 169590-41-4
-
Appearance Solid
-
분자량 397.37
-
화학식 C17H14F3N3O3S
-
Color Light yellow to yellow
-
SMILES
O=S(C1=CC=C(N2N=C(C(F)F)C=C2C3=CC=C(OC)C(F)=C3)C=C1)(N)=O
-
Synonyms
SC 046; SC 46; SC 59046
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
J Cachexia Sarcopenia Muscle
Celecoxib Enhances Oxidative Muscle Fibre Formation and Improves Muscle Functions Through Prokr1 Activation in Mice. [Abstract]2025 Feb;16(1):e13704. PMID: 39887895
용액&용해도
DMSO : 50 mg/mL (125.83 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.29 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.29 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (284 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Royals, S.R., et al., Investigation of the effects of deracoxib and piroxicam on the in vitro viability of osteosarcoma cells from dogs. Am J Vet Res, 2005. 66(11): p. 1961-7. [Content Brief]
[2]. Ustun Alkan, F., et al., The effects of piroxicam and deracoxib on canine mammary tumour cell line. ScientificWorldJournal, 2012. 2012: p. 976740. [Content Brief]
[3]. Bienhoff, S.E., et al., Efficacy and safety of deracoxib for control of postoperative pain and inflammation associated with soft tissue surgery in dogs. Vet Surg, 2012. 41(3): p. 336-44. [Content Brief]
[4]. McMillan, S.K., et al., Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc, 2011. 239(8): p. 1084-9. [Content Brief]
[5]. Anderson GD, et al. Combination therapies that inhibit cyclooxygenase-2 and leukotriene synthesis prevent disease in murine collagen induced arthritis. Inflamm Res. 2009 Feb;58(2):109-17. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5165 mL | 12.5827 mL | 25.1655 mL | 62.9137 mL |
| 5 mM | 0.5033 mL | 2.5165 mL | 5.0331 mL | 12.5827 mL | |
| 10 mM | 0.2517 mL | 1.2583 mL | 2.5165 mL | 6.2914 mL | |
| 15 mM | 0.1678 mL | 0.8388 mL | 1.6777 mL | 4.1942 mL | |
| 20 mM | 0.1258 mL | 0.6291 mL | 1.2583 mL | 3.1457 mL | |
| 25 mM | 0.1007 mL | 0.5033 mL | 1.0066 mL | 2.5165 mL | |
| 30 mM | 0.0839 mL | 0.4194 mL | 0.8388 mL | 2.0971 mL | |
| 40 mM | 0.0629 mL | 0.3146 mL | 0.6291 mL | 1.5728 mL | |
| 50 mM | 0.0503 mL | 0.2517 mL | 0.5033 mL | 1.2583 mL | |
| 60 mM | 0.0419 mL | 0.2097 mL | 0.4194 mL | 1.0486 mL | |
| 80 mM | 0.0315 mL | 0.1573 mL | 0.3146 mL | 0.7864 mL | |
| 100 mM | 0.0252 mL | 0.1258 mL | 0.2517 mL | 0.6291 mL |
Deracoxib Related Classifications
HY-17509 Related Classifications
Powered by Bioz